— STARLYS trial to evaluate the potential of MST-0312, a targeted lymphotoxin-beta (LTBR) agonist bispecific antibody, as a novel therapeutic strategy for the treatment of solid tumors. — Study to evaluate tertiary lymphoid structure (TLS) and high endothelial venule (HEV) formation in the tumor as well as clinical responses, as monotherapy and in combination with […]
First-in-class oral therapy ATR-258 mimics the effects of exercise – driving fat loss, increasing muscle, and improving metabolism – with broad potential as a novel treatment for muscle-sparing weight loss Study led by Associate Professor Morten Hostrup, a leading authority on β2-adrenergic receptor signaling in skeletal muscle at the University of Copenhagen, to evaluate muscle […]
Phase I results demonstrate favorable safety, sustained target engagement, and early signs of anti-tumor activity Reinforce EP4 receptor antagonism as a validated, high-value strategy to overcome immunotherapy resistance Montreal, Canada – Strasbourg, France – Boston, United States, March 10, 2026: Kainova Therapeutics (“the Company”), a key player for breakthrough treatments in immuno-oncology and inflammation, today […]
AP31969 is a novel, first-in-class, oral SK ion channel inhibitor intended for rhythm control of atrial fibrillation and has recently completed Phase 1 in healthy volunteers Phase 2 trial will assess the efficacy of AP31969 on atrial fibrillation burden and its safety profile using continuous cardiac rhythm monitoring Copenhagen, Denmark, 6 January 2026 – Acesion […]
Differentiated profile of ALY-301 designed to enable chronic dosing in mast cell dependent diseases while avoiding the safety limitations of conventional c-Kit inhibitors Multicenter Phase 1/1b study to enroll both healthy volunteers and patients with Cold Urticaria with initial data readouts expected in 2026 Boston, Massachusetts and Lausanne, Switzerland, 30 October 2025 – Alys Pharmaceuticals, […]
